




The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 1.8% points. The greatest weakness of CTI Biopharma CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 122% points below the market average of 263%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	134,975	Assets	144,332
Cost of Goods Sold	0	Liabilities	96,919
Intangible Assets	0	Expenses	132,782
Liabilities, Current	72,409	Revenues	16,116
Liabilities, Non-Current	23,400	Stockholders Equity	47,413
Other Assets	5,639	Net Income	-120,763
Other Compr. Net Income	888	Comprehensive Net Income	-120,319
Other Expenses	2,193	BaseVar	197,567
Other Liabilities	1,110	ECR before LimitedLiability	-14%
Other Net Income	-4,097	Economic Capital Ratio	141%
Other Revenues	16,116		
Property and Equipment	3,718		
Research and Development	76,627		
Selling, General and Administrative Expense	53,962		